|
1
|
Mendes D, Alves C, Afonso N, Cardoso F,
Passos-Coelho JL, Costa L, Andrade S and Batel-Marques F: The
benefit of HER2-targeted therapies on overall survival of patients
with metastatic HER2-positive breast cancer - a systematic review.
Breast Cancer Res. 17:1402015. View Article : Google Scholar
|
|
2
|
Fan W, Chang J and Fu P: Endocrine therapy
resistance in breast cancer: Current status, possible mechanisms
and overcoming strategies. Future Med Chem. 7:1511–1519. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Z, Shi T, Zhang L, Zhu P, Deng M,
Huang C, Hu T, Jiang L and Li J: Mammalian drug efflux transporters
of the ATP binding cassette (ABC) family in multidrug resistance: A
review of the past decade. Cancer Lett. 370:153–164. 2016.
View Article : Google Scholar
|
|
4
|
Ailles LE and Weissman IL: Cancer stem
cells in solid tumors. Curr Opin Biotechnol. 18:460–466. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takebe N, Harris PJ, Warren RQ and Ivy SP:
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog
pathways. Nat Rev Clin Oncol. 8:97–106. 2011. View Article : Google Scholar
|
|
7
|
Yuan TL and Cantley LC: PI3K pathway
alterations in cancer: Variations on a theme. Oncogene.
27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baselga J: Targeting the
phosphoinositide-3 (PI3) kinase pathway in breast cancer.
Oncologist. 16(Suppl 1): 12–19. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Burris HA III: Overcoming acquired
resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR
pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maira SM, Pecchi S, Huang A, Burger M,
Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, et al:
Identification and characterization of NVP-BKM120, an orally
available pan-class I PI3-kinase inhibitor. Mol Cancer Ther.
11:317–328. 2012. View Article : Google Scholar
|
|
12
|
Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li
H, Lin H, Lan Y, Liu Z, He J, et al: Novel phosphatidylinositol
3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells
and shows synergistic anti-myeloma activity with dexamethasone. J
Mol Med Berl. 90:695–706. 2012. View Article : Google Scholar
|
|
13
|
Amrein L, Shawi M, Grenier J, Aloyz R and
Panasci L: The phosphatidylinositol-3 kinase I inhibitor BKM120
induces cell death in B-chronic lymphocytic leukemia cells in
vitro. Int J Cancer. 133:247–252. 2013. View Article : Google Scholar
|
|
14
|
Bendell JC, Rodon J, Burris HA, de Jonge
M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, et
al: Phase I, dose-escalation study of BKM120, an oral pan-Class I
PI3K inhibitor, in patients with advanced solid tumors. J Clin
Oncol. 30:282–290. 2012. View Article : Google Scholar
|
|
15
|
O'Brien NA, McDonald K, Tong L, von Euw E,
Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz
R, et al: Targeting PI3K/mTOR overcomes resistance to HER2-targeted
therapy independent of feedback activation of AKT. Clin Cancer Res.
20:3507–3520. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ren H, Chen M, Yue P, Tao H, Owonikoko TK,
Ramalingam SS, Khuri FR and Sun SY: The combination of RAD001 and
NVP-BKM120 synergistically inhibits the growth of lung cancer in
vitro and in vivo. Cancer Lett. 325:139–146. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jane EP, Premkumar DR, Morales A, Foster
KA and Pollack IF: Inhibition of phosphatidylinositol 3-kinase/AKT
signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a
caspase-dependent manner through mitochondrial dysfunction and DNA
damage response in established and primary cultured glioblastoma
cells. J Pharmacol Exp Ther. 350:22–35. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Silvera D, Formenti SC and Schneider RJ:
Translational control in cancer. Nat Rev Cancer. 10:254–266. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Albiges L, Kube U, Eymard JC, Schmidinger
M, Bamias A, Kelkouli N, Mraz B, Florini S, Guderian G, Cattaneo A,
et al: Everolimus for patients with metastatic renal cell carcinoma
refractory to anti-VEGF therapy: Results of a pooled analysis of
non-interventional studies. Eur J Cancer. 51:2368–2374. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
O'Reilly KE, Rojo F, She QB, Solit D,
Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al:
mTOR inhibition induces upstream receptor tyrosine kinase signaling
and activates Akt. Cancer Res. 66:1500–1508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang X, Yue P, Kim YA, Fu H, Khuri FR and
Sun SY: Enhancing mammalian target of rapamycin (mTOR)-targeted
cancer therapy by preventing mTOR/raptor inhibition-initiated,
mTOR/rictor-independent Akt activation. Cancer Res. 68:7409–7418.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gioanni J, Le François D, Zanghellini E,
Mazeau C, Ettore F, Lambert JC, Schneider M and Dutrillaux B:
Establishment and characterisation of a new tumorigenic cell line
with a normal karyotype derived from a human breast adenocarcinoma.
Br J Cancer. 62:8–13. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Holliday DL and Speirs V: Choosing the
right cell line for breast cancer research. Breast Cancer Res.
13:2152011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lombardo Y, Filipović A, Molyneux G,
Periyasamy M, Giamas G, Hu Y, Trivedi PS, Wang J, Yagüe E, Michel
L, et al: Nicastrin regulates breast cancer stem cell properties
and tumor growth in vitro and in vivo. Proc Natl Acad Sci USA.
109:16558–16563. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lombardo Y, de Giorgio A, Coombes CR,
Stebbing J and Castellano L: Mammosphere formation assay from human
breast cancer tissues and cell lines. J Vis Exp. 97:e526712015.
|
|
26
|
Hu Y, Cheng X, Li S, Zhou Y, Wang J, Cheng
T, Yang M and Xiong D: Inhibition of sorcin reverses multidrug
resistance of K562/A02 cells and MCF-7/A02 cells via regulating
apoptosis-related proteins. Cancer Chemother Pharmacol. 72:789–798.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou Y, Hu Y, Yang M, Jat P, Li K,
Lombardo Y, Xiong D, Coombes RC, Raguz S and Yagüe E: The
miR-106b~25 cluster promotes bypass of doxorubicin-induced
senescence and increase in motility and invasion by targeting the
E-cadherin transcriptional activator EP300. Cell Death Differ.
21:462–474. 2014. View Article : Google Scholar
|
|
29
|
Ponti D, Costa A, Zaffaroni N, Pratesi G,
Petrangolini G, Coradini D, Pilotti S, Pierotti MA and Daidone MG:
Isolation and in vitro propagation of tumorigenic breast cancer
cells with stem/progenitor cell properties. Cancer Res.
65:5506–5511. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Grimshaw MJ, Cooper L, Papazisis K,
Coleman JA, Bohnenkamp HR, Chiapero-Stanke L, Taylor-Papadimitriou
J and Burchell JM: Mammosphere culture of metastatic breast cancer
cells enriches for tumorigenic breast cancer cells. Breast Cancer
Res. 10:R522008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar
|
|
32
|
Calcagno AM, Salcido CD, Gillet JP, Wu CP,
Fostel JM, Mumau MD, Gottesman MM, Varticovski L and Ambudkar SV:
Prolonged drug selection of breast cancer cells and enrichment of
cancer stem cell characteristics. J Natl Cancer Inst.
102:1637–1652. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang X, Zhang S, Liu Y, Liu J, Ma Y, Zhu
Y and Zhang J: Effects of the combination of RAD001 and docetaxel
on breast cancer stem cells. Eur J Cancer. 48:1581–1592. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Miller TW, Balko JM and Arteaga CL:
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast
cancer. J Clin Oncol. 29:4452–4461. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ghebeh H, Al-Khaldi S, Olabi S, Al-Dhfyan
A, Al-Mohanna F, Barnawi R, Tulbah A, Al-Tweigeri T, Ajarim D and
Al-Alwan M: Fascin is involved in the chemotherapeutic resistance
of breast cancer cells predominantly via the PI3K/Akt pathway. Br J
Cancer. 111:1552–1561. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu Y, Zhang X, Liu J, Hou G, Zhang S and
Zhang J: Everolimus in combination with letrozole inhibit human
breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: An
experimental study. Tumour Biol. 35:1275–1286. 2014. View Article : Google Scholar
|
|
37
|
Zhu Y, Zhang X, Liu Y, Zhang S, Liu J, Ma
Y and Zhang J: Antitumor effect of the mTOR inhibitor everolimus in
combination with trastuzumab on human breast cancer stem cells in
vitro and in vivo. Tumour Biol. 33:1349–1362. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Passacantilli I, Capurso G, Archibugi L,
Calabretta S, Caldarola S, Loreni F, Delle Fave G and Sette C:
Combined therapy with RAD001 e BEZ235 overcomes resistance of PET
immortalized cell lines to mTOR inhibition. Oncotarget.
5:5381–5391. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bareschino MA, Schettino C, Rossi A,
Maione P, Sacco PC, Zeppa R and Gridelli C: Treatment of advanced
non small cell lung cancer. J Thorac Dis. 3:122–133. 2011.
|
|
40
|
Harris CA, Ward RL, Dobbins TA, Drew AK
and Pearson S: The efficacy of HER2-targeted agents in metastatic
breast cancer: A meta-analysis. Ann Oncol. 22:1308–1317. 2011.
View Article : Google Scholar
|
|
41
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang
Y, Deng J, Margolick JB, Liotta LA, Petricoin E III and Zhang Y:
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer
stem-like cells is required for viability and maintenance. Proc
Natl Acad Sci USA. 104:16158–16163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gupta PB, Onder TT, Jiang G, Tao K,
Kuperwasser C, Weinberg RA and Lander ES: Identification of
selective inhibitors of cancer stem cells by high-throughput
screening. Cell. 138:645–659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Airiau K, Mahon FX, Josselin M, Jeanneteau
M and Belloc F: PI3K/mTOR pathway inhibitors sensitize chronic
myeloid leukemia stem cells to nilotinib and restore the response
of progenitors to nilotinib in the presence of stem cell factor.
Cell Death Dis. 4:e8272013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang XQ, Ongkeko WM, Chen L, Yang ZF, Lu
P, Chen KK, Lopez JP, Poon RT and Fan ST: Octamer 4 (Oct4) mediates
chemotherapeutic drug resistance in liver cancer cells through a
potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology.
52:528–539. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Peiró G, Ortiz-Martínez F, Gallardo A,
Pérez-Balaguer A, Sánchez-Payá J, Ponce JJ, Tibau A, López-Vilaro
L, Escuin D, Adrover E, et al: Src, a potential target for
overcoming trastuzumab resistance in HER2-positive breast
carcinoma. Br J Cancer. 111:689–695. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pandya K, Wyatt D, Gallagher B, Shah D,
Baker A, Bloodworth J, Zlobin A, Pannuti A, Green A, Ellis IO, et
al: PKCα attenuates Jagged-1-mediated Notch signaling in
ErbB-2-positive breast cancer to reverse trastuzumab resistance.
Clin Cancer Res. 22:175–186. 2016. View Article : Google Scholar
|
|
48
|
Berns K, Horlings HM, Hennessy BT,
Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM,
Stemke-Hale K, Hauptmann M, et al: A functional genetic approach
identifies the PI3K pathway as a major determinant of trastuzumab
resistance in breast cancer. Cancer Cell. 12:395–402. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhu Y, Tian T, Zou J, Wang Q, Li Z, Li Y,
Liu X, Dong B, Li N, Gao J, et al: Dual PI3K/mTOR inhibitor BEZ235
exerts extensive antitumor activity in HER2-positive gastric
cancer. BMC Cancer. 15:8942015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Elster N, Cremona M, Morgan C, Toomey S,
Carr A, O'Grady A, Hennessy BT and Eustace AJ: A preclinical
evaluation of the PI3K alpha/delta dominant inhibitor BAY 80–6946
in HER2-positive breast cancer models with acquired resistance to
the HER2-targeted therapies trastuzumab and lapatinib. Breast
Cancer Res Treat. 149:373–383. 2015. View Article : Google Scholar
|
|
51
|
Saura C, Bendell J, Jerusalem G, Su S, Ru
Q, De Buck S, Mills D, Ruquet S, Bosch A, Urruticoechea A, et al:
Phase Ib study of Buparlisib plus Trastuzumab in patients with
HER2-positive advanced or metastatic breast cancer that has
progressed on Trastuzumab-based therapy. Clin Cancer Res.
20:1935–1945. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Rodler E, Korde L and Gralow J: Current
treatment options in triple negative breast cancer. Breast Dis.
32:99–122. 2010.
|
|
54
|
Ibrahim YH, García-García C, Serra V, He
L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J,
et al: PI3K inhibition impairs BRCA1/2 expression and sensitizes
BRCA-proficient triple-negative breast cancer to PARP inhibition.
Cancer Discov. 2:1036–1047. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yunokawa M, Koizumi F, Kitamura Y,
Katanasaka Y, Okamoto N, Kodaira M, Yonemori K, Shimizu C, Ando M,
Masutomi K, et al: Efficacy of everolimus, a novel mTOR inhibitor,
against basal-like triple-negative breast cancer cells. Cancer Sci.
103:1665–1671. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Singh J, Novik Y, Stein S, Volm M, Meyers
M, Smith J, Omene C, Speyer J, Schneider R, Jhaveri K, et al: Phase
2 trial of everolimus and carboplatin combination in patients with
triple negative metastatic breast cancer. Breast Cancer Res.
16:R322014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue
P, Fu H and Khuri FR: Activation of Akt and eIF4E survival pathways
by rapamycin-mediated mammalian target of rapamycin inhibition.
Cancer Res. 65:7052–7058. 2005. View Article : Google Scholar : PubMed/NCBI
|
